Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.
What is the anticipated market size of the hematologic malignancies detection industry over the next few years?
The hematologic malignancies detection market size has grown rapidly in recent years. It will grow from $2.68 $ billion in 2024 to $3.1 $ billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth in the historic period can be attributed to rising incidence rates of conditions, increased awareness about their importance, increased demand from both patients, supportive regulatory frameworks, and the rise of digital health technology.
The hematologic malignancies detection market size is expected to see rapid growth in the next few years. It will grow to $5.46 $ billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to expanding healthcare infrastructure, government initiatives and funding, the expansion of health insurance coverage, and improvements in data management systems. Major trends in the forecast period include enhanced resolution of genetic and epigenetic data, advanced techniques for profiling protein expressions, enhanced immunoassay techniques, the development of nanomaterials and nano sensors, and the expansion of telemedicine platforms.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the hematologic malignancies detection market?
The increasing prevalence of blood cancer is expected to propel the growth of the hematologic malignancy detection market going forward. Blood cancer is a group of cancers affecting the blood, bone marrow, or lymphatic system, disrupting average blood cell production and function. The prevalence of blood cancer is due to aging populations and improved diagnostic techniques that lead to earlier and more accurate detection. Hematologic malignancy detection is essential for blood cancer treatment as it enables early and accurate diagnosis, allowing for personalized and effective treatment strategies. For instance, in March 2024, according to a Cancer Facts & Figures 2023 report published by the Leukemia & Lymphoma Society, a US-based professional organization company, approximately 437,337 people are living with or remission from leukemia in the US. Further, around 59,610 new cases are expected to be diagnosed in 2024. Therefore, the increasing prevalence of blood cancer is driving the growth of the hematologic malignancy detection market.
What emerging segments are shaping the future landscape of the hematologic malignancies detection industry?
The hematologic malignancies detection market covered in this report is segmented –
1) By Type: Polymerase Chain Reaction, Immunochemistry, Next Generation Sequencing, Fluorescence In Situ Hybridization, Other Types
2) By Application: Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Myeloproliferative Neoplasms, Lymphoma, Other Application
3) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Polymerase Chain Reaction (PCR): Real-Time PCR (qPCR), Digital PCR, Reverse Transcription PCR (RT-PCR), Nested PCR, Multiplex PCR, PCR-Based Detection Kits
2) By Immunochemistry: Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry (IHC), Western Blotting, Flow Cytometry, Immunofluorescence, Immunohistochemical Staining Kits
3) By Next Generation Sequencing (NGS): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq), Liquid Biopsy NGS, Next-Generation Sequencing Kits For Hematologic Malignancies
4) By Fluorescence In Situ Hybridization (FISH): Chromosome-Specific FISH Probes, DNA FISH, RNA FISH, Multicolor FISH, FISH-Based Detection Kits For Leukemia And Lymphoma
5) By Other Types: Cytogenetic Testing, Cytometry-Based Detection, Magnetic Resonance Imaging (MRI) For Detection, High-Performance Liquid Chromatography (HPLC), Mass Spectrometry For Hematologic Malignancies Detection
View The Full Market Report:
Which trends are expected to dominate the hematologic malignancies detection market landscape in the coming years?
Major companies operating in the hematologic malignancy detection market are focusing on developing innovative solutions, such as blood cancer diagnostic tests, to enhance diagnostic accuracy and improve patient outcomes. Blood cancer diagnostic tests are crucial for identifying and confirming the presence of hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment center, launched PanHeme, an advanced blood cancer diagnostic test that utilizes next-generation gene sequencing technology for hematologic malignancy detection. Utilizing next-generation sequencing technology, PanHeme identifies genetic mutations in blood cancers such as leukemia, lymphoma, and multiple myeloma within 72 hours, significantly faster than traditional methods. This rapid turnaround enables personalized treatment plans by allowing healthcare providers to utilize targeted FDA-approved therapies based on specific mutations.
How are key players in the hematologic malignancies detection market strengthening their market position?
Major companies operating in the hematologic malignancies detection market are AbbVie Inc., Sanofi-Aventis U.S LLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Novartis AG, Becton Dickinson and Company, Laboratory Corporation of America Holdings, ICON plc, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Kite Pharma Inc., ArcherDx Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Tempus Labs Inc., Adaptive Biotechnologies Corporation, Freenome Inc., Invivoscribe Technologies Inc., Asuragen Inc., Celldex Therapeutics Inc.
Which geographic areas are contributing significantly to the growth of the hematologic malignancies detection sector?
North America was the largest region in the hematologic malignancies’ detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Hematologic Malignancies Detection Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Hematologic Malignancies Detection Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment